For example, in a recent study, combining HC-5404 PERK inhibitor with VEGF receptor tyrosine kinase inhibitors, such as Axitinib and Lenvatinib, significantly enhanced the anti-tumor and antiangiogenic effects of these drugs in multiple renal cell carcinoma xenograft tumor models [242]. The gene discussed is EIF2AK3; the disease is neoplasm.